The lawsuit comes after a federal appeals court in December rejected
Moderna's challenge to patents belonging to Arbutus Biopharma that
were licensed to Genevant Sciences Inc.
The court let stand an administrative panel's findings that Arbutus'
patents - which may cover technology used in the vaccines - were
valid, as the science involved was not previously known.
Moderna did not immediately respond to a Reuters request for
comment.
Arbutus and Genevant do not seek to interfere with the sale,
manufacturing or distribution of Moderna's COVID-19 vaccine, said
Arbutus Chief Executive Officer William Collier in a statement.
![](http://archives.lincolndailynews.com/2022/Feb/28/images/ads/current/castlemanor_sda_FINANCIAL_2017.png)
[to top of second column] |
![](http://archives.lincolndailynews.com/2022/Feb/28/images/ads/current/debbiesfloral_lda_021022.png) "However, we seek fair compensation for
Moderna's use of our patented technology that
was developed with great effort and at great
expense, without which Moderna's COVID-19
vaccine would not have been successful."
Genevant Sciences was launched in 2018 by
Arbutus and Roivant Sciences Ltd. Roivant owns
about 80% of Genevant and Arbutus holds the
remainder stake.
(Reporting by Amruta Khandekar; Editing by
Shinjini Ganguli)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |